Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.

Area of Science:

• Neuro-oncology
• Hematology
• Oncology

Background:

• Patients with primary or metastatic brain tumors face elevated risks of venous thromboses.
• Balancing the benefits of anticoagulation against the risk of intracranial hemorrhage is critical.

Observation:

• The risk of spontaneous intracranial bleeding in most primary and treated metastatic brain tumors is acceptable.
• Therapeutic anticoagulation with low molecular weight heparin or direct oral anticoagulants does not significantly increase bleeding risk in these patients.
• Thrombocytopenia and other coagulopathies are contraindications for anticoagulation.

Findings:

• Malignant gliomas present increased risks for both venous thromboses and intracranial hemorrhage.
• Therapeutic anticoagulation is acceptable for most treated brain metastases, with low molecular weight heparin as a preferred agent.
• Patients with untreated metastases from melanoma, renal cell carcinoma, choriocarcinoma, thyroid, and hepatocellular carcinoma have a higher propensity for spontaneous bleeding.

Implications:

• Careful therapeutic anticoagulation can be considered for most patients with primary or treated metastatic brain tumors.
• Routine brain imaging and alternative strategies (e.g., IVC filter) are recommended for patients with specific untreated brain metastases due to high bleeding risk.
• Systemic anticoagulation may be contraindicated in the acute setting of venous thromboembolism for patients with high-risk untreated brain metastases.